Drug Trial Radar · NCT00251004
Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
Last checked: Nov 20, 2026Latest source record: May 10, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
833
Actual
Start
Oct 2005
Primary completion
Aug 2009
Study completion Oct 2009
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Nov 9, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study was to compare the safety and efficacy of three immunosuppressive treatment regimens following a kidney transplant.
Conditions
- Kidney Transplantation
- Graft Rejection
Interventions
EverolimusDrug
oral, bis in diem/twice a day (bid)
Mycophenolic Acid (MPA)Drug
2 oral capsules of mycophenolic acid 360mg administered bid
Cyclosporine A (CsA)Drug
CsA dose adjustments were based on CsA trough levels (C0).
BasiliximabDrug
All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.
CorticosteroidsDrug
Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Composite Efficacy Endpoints - 12 Month AnalysisTime frame: 12 months
- Non-inferiority Analysis on Percentage of Participants With Composite Efficacy EndpointsTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Novartis
East Hanover, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.